{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:03:21Z","timestamp":1759104201168,"version":"3.44.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jneuroim.2014.10.011","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T02:45:21Z","timestamp":1414982721000},"page":"6-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy"],"prefix":"10.1016","volume":"277","author":[{"given":"Federico","family":"Serana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chiarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Sottini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Giustini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Vaglio Tessitore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-769X","authenticated-orcid":false,"given":"Luisa","family":"Imberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2014.10.011_bb0005","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00415-012-6426-5","article-title":"Value of MRI as a surrogate marker for PML in natalizumab long-term therapy","volume":"259","author":"Ayzenberg","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0010","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0015","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/eji.201242517","article-title":"Next generation sequencing for TCR repertoire profiling: platform-specific features and correction algorithms","volume":"42","author":"Bolotin","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0025","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1182\/blood-2011-08-371021","article-title":"Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR","volume":"119","author":"Borte","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0030","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0045","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","article-title":"Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease","volume":"56","author":"Calabrese","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0050","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11910-013-0408-6","article-title":"Progressive multifocal leukoencephalopathy in multiple sclerosis","volume":"13","author":"Chalkley","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0330","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0060","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/1352458509355460","article-title":"Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate","volume":"16","author":"Chiarini","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0065","article-title":"Newly produced T- and B-lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients","author":"Chiarini","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0070","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0075","article-title":"Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients","author":"Cordioli","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0080","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","article-title":"Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?","volume":"20","author":"Cutter","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0085","doi-asserted-by":"crossref","first-page":"e34103","DOI":"10.1371\/journal.pone.0034103","article-title":"Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis","volume":"7","author":"de Andr\u00e9s","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0090","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.05.017","article-title":"Cloning of the first human anti-JCPyV\/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy","volume":"108","author":"Diotti","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.2012.01881.x","article-title":"HLA DNA typing: past, present, and future","volume":"80","author":"Erlich","year":"2012","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0100","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nri1710","article-title":"Fuel feeds function: energy metabolism and the T-cell response","volume":"5","author":"Fox","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0105","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0110","first-page":"S507","article-title":"ImmuKnow (Cylex) does not appear to be useful for PML risk stratification with natalizumab treatment","volume":"17","author":"Goelz","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0165-5728(97)00250-6","article-title":"Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis","volume":"85","author":"Gran","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0125","doi-asserted-by":"crossref","first-page":"e18506","DOI":"10.1371\/journal.pone.0018506","article-title":"Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders","volume":"6","author":"Haghikia","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0130","doi-asserted-by":"crossref","first-page":"e31784","DOI":"10.1371\/journal.pone.0031784","article-title":"Lymphocyte subsets show different response patterns to in vivo bound natalizumab\u2014a flow cytometric study on patients with multiple sclerosis","volume":"7","author":"Harrer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0135","first-page":"S98","article-title":"Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host","volume":"6","author":"Hou","year":"2000","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(10)70006-5","article-title":"Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study","volume":"9","author":"Jilek","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1352458513513208","article-title":"Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 \u03b1-chain (CD11a) in MS patients","volume":"7","author":"Jilek","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0150","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1093\/brain\/awm214","article-title":"Multiple sclerosis: T-cell receptor expression in distinct brain regions","volume":"130","author":"Junker","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40259-013-0011-z","article-title":"Immunotherapy of multiple sclerosis: the state of the art","volume":"27","author":"Karussis","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0165","series-title":"Neurotropic Virus Infections","first-page":"190","article-title":"JC virus molecular biology and the human demyelinating disease, progressive multifocal leukoencephalopathy","author":"Khalili","year":"2008"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cei.12261","article-title":"Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab","volume":"176","author":"Koudriavtseva","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0180","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2012-302478","article-title":"Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies","volume":"83","author":"Mentzer","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0185","doi-asserted-by":"crossref","DOI":"10.1177\/1352458514534513","article-title":"Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","author":"Mu\u00f1oz-Culla","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jneuroim.2005.10.002","article-title":"Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis","volume":"171","author":"Muraro","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0195","doi-asserted-by":"crossref","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0200","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/pds.3414","article-title":"Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants","volume":"22","author":"Piccinni","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","article-title":"Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients","volume":"204","author":"Reid","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0215","first-page":"S23","article-title":"Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV status","volume":"258","author":"Sandrock","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0220","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/pds.3320","article-title":"Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)","volume":"21","author":"Schmedt","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0225","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/QAD.0000000000000201","article-title":"Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection","volume":"28","author":"Schneider-Hohendorf","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0230","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0235","first-page":"e39","article-title":"Comparison and correlation of two proposed PML risk stratification biomarkers for long-term Natalizumab treatment, anti-JCV antibody index and L-selection (CD62L): a retrospective study","volume":"83","author":"Schwab","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.clim.2012.04.002","article-title":"Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects","volume":"144","author":"Sievers","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0250","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clim.2010.04.005","article-title":"Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation","volume":"136","author":"Sottini","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0245","doi-asserted-by":"crossref","first-page":"e34493","DOI":"10.1371\/journal.pone.0034493","article-title":"Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient","volume":"7","author":"Sottini","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0255","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2008.03.022","article-title":"The effects of natalizumab on the innate and adaptive immune system in the central nervous system","volume":"274","author":"St\u00fcve","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0260","doi-asserted-by":"crossref","first-page":"e1004084","DOI":"10.1371\/journal.ppat.1004084","article-title":"JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants","volume":"10","author":"Sundqvist","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0265","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0270","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing\u2013remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0275","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e31820b7644","article-title":"Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS","volume":"76","author":"Vennegoor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0280","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0b013e3182a84101","article-title":"Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis","volume":"81","author":"Warnke","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","author":"Warnke","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0290","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00415-014-7336-5","article-title":"Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?","volume":"261","author":"Wattjes","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0295","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ana.1004","article-title":"Cellular and humoral immune response in progressive multifocal leukoencephalopathy","volume":"49","author":"Weber","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2010.09.021","article-title":"Progressive multifocal leukoencephalopathy","volume":"231","author":"Weissert","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0305","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1352458510383075","article-title":"Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment","volume":"17","author":"Wipfler","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clim.2012.07.007","article-title":"Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients","volume":"145","author":"Zanotti","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0320","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","article-title":"The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans","volume":"111","author":"Zohren","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2014.10.011_bb0325","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.4238\/2014.February.28.1","article-title":"Preliminary study of the clonal characteristics of the TCRBV subfamilies in T cells in the peripheral blood from patients with uveitis","volume":"13","author":"Zou","year":"2014","journal-title":"Genet. Mol. Res."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281400945X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557281400945X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:23:34Z","timestamp":1759047814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557281400945X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":66,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S016557281400945X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.10.011","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2014.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}